BioSpace News Archive

Italfarmaco Group announced that the U.S. Food and Drug Administration has completed its filing review and accepted the company’s New Drug Application for Givinostat.

Kineta, Inc. announced the achievement of a development milestone which triggers a $5 million payment from its research and development collaboration with Merck.

Merck, known as MSD outside of the United States and Canada, will hold its second-quarter 2023 sales and earnings conference call with institutional investors and analysts at 8:00 a.m. ET on Tuesday, Aug. 1.

Jacobio Pharma announced clinical results of its novel KRAS G12C inhibitor glecirasib monotherapy and in combination therapy with cetuximab to treat KRAS G12C mutant advanced CRC in Second JCA- AACR Precision Medicine International Conference.

Biosyngen, an immune-oncology company with technology targeting the unmet medical needs in solid tumour and lymphoma treatment, announced the official opening of its latest Good Manufacturing Practice facility in Singapore.

BioXcel Therapeutics, Inc. announced positive topline results for TRANQUILITY II, a Phase 3 trial of BXCL501, the Company’s proprietary, orally dissolving film formulation of dexmedetomidine under investigation for the acute treatment of Alzheimer’s disease-related agitation.

MediciNova, Inc. announced that Principal Investigator, Lara Ray, PhD, Professor, Department of Psychology, University of California Los Angeles presented the results of the Phase 2b trial of MN-166 in alcohol use disorder at the 46th Annual Research Society on Alcoholism Scientific Meeting held June 24 - 28, 2023, in Bellevue, Washington.

Axonics, Inc., a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, will report second quarter 2023 financial results after the close of trading on Thursday, July 27.

Rockwell Medical, Inc. announced that the Company entered into a three-year co-promotion services agreement with B. Braun Medical Inc., a leader in renal therapies including innovative, high-quality products for hemodialysis.

Immunic, Inc. announced participation in the following scientific and investor conferences in July.